SCHEMBL266162

SCHEMBL266162

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2c(C)csc2C(=O)N/N=C/c2ccc(OC)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
MAPT P10636 4/20 0.43
POLB P06746 1/20 0.43
SLC34A2 O95436 2/20 0.42
ALDH1A1 P00352 3/20 0.41
SPHK2 Q9NRA0 2/20 0.41
SPHK1 Q9NYA1 2/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
HIF1A Q16665 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 2/20 0.40
BCHE P06276 1/20 0.39
ATM Q13315 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266163 1.00 KDM4E (0.43) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL266602 0.93 SLC34A2 (0.43) KDM4EMAPTSLC34A2ALDH1A1SMN1; SMN2
SCHEMBL266601 0.93 SLC34A2 (0.43) KDM4EMAPTSLC34A2ALDH1A1SMN1; SMN2
SCHEMBL267625 0.92 RAB9A (0.45) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL267624 0.92 RAB9A (0.45) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL267417 0.91 SLC34A2 (0.44) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL267418 0.91 SLC34A2 (0.44) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL268123 0.89 SLC34A2 (0.47) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL268124 0.89 SLC34A2 (0.47) KDM4EMAPTPOLBSLC34A2ALDH1A1
SCHEMBL267125 0.88 SLC34A2 (0.43) MAPTPOLBSLC34A2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885MAPT 4195/4885POLB 3843/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885MAPT 4648/4885POLB 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.